Ginkgo Bioworks DNA Debt-to-equity

Debt-to-equity at other companies

Thermo Fisher ScientificTMO

0.7×0.0×

Charles River LaboratoriesCRL

1.1×+0.2×

AbCellera Biologics Inc.ABCL

0.2×0.0×

eXoZymes, Inc.EXOZ

0.8×+0.6×

TEC

Bio-TechneTECH

0.1×-0.1×

RevvityRVTY

0.5×+0.1×

FAQ

What is Ginkgo Bioworks's debt-to-equity?

Ginkgo Bioworks (DNA) reported debt-to-equity of 1× in Q2 2026.

How has Ginkgo Bioworks's debt-to-equity changed year-over-year?

Ginkgo Bioworks's debt-to-equity increased by 37.4% year-over-year, from 0.7× to 1×.

What is the long-term trend for Ginkgo Bioworks's debt-to-equity?

Over 5 years (2020 to 2025), Ginkgo Bioworks's debt-to-equity has grown at a 89.1% compound annual growth rate (CAGR), from 0× to 0.9×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.